CTI BioPharma Corp. (CTIC)

$ 2.67
-0.04 (-1.48%)
Neutral
Symbol CTIC
Price $ 2.67
Beta 0.760
Volume Avg. 0.79M
Market Cap 0.25B
Shares () -
52 Week Range 2.15-4.13
1y Target Est -
DCF Unlevered CTIC DCF ->
DCF Levered CTIC LDCF ->
ROE -144.30% Strong Sell
ROA -81.56% Strong Sell
Operating Margin -
Debt / Equity 25.59% Neutral
P/E -
P/B 3.30 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest CTIC news


Dr. Adam R. Craig
Healthcare
Biotechnology
Nasdaq Capital Market

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.